Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab versus fingolimod in pediatric relapsing-remitting multiple sclerosis
NL-OMON59557Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ocrelizumab and fingolimod in multiple sclerosis (MS), sponsored by Roche. Primary endpoint: Protocol-defined annualized relapse rate. Started Jan 2023; status: completed.
02
Drugs
ocrelizumabfingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON59557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59557.